journal article·2022-08-07Open access

Application of Biocompatible Drug Delivery Nanosystems for the Treatment of Naturally Occurring Cancer in Dogs

Nicola Ambrosio, Silvia Voci, Agnese Gagliardi, Ernesto Palma, Massimo Fresta, Donato Cosco

Abstract

Background: Cancer is a common disease in dogs, with a growing incidence related to the age of the animal. Nanotechnology is being employed in the veterinary field in the same manner as in human therapy. Aim: This review focuses on the application of biocompatible nanocarriers for the treatment of canine cancer, paying attention to the experimental studies performed on dogs with spontaneously occurring cancer. Methods: The most important experimental investigations based on the use of lipid and non-lipid nanosystems proposed for the treatment of canine cancer, such as liposomes and polymeric nanoparticles containing doxorubicin, paclitaxel and cisplatin, are described and their in vivo fate and antitumor features discussed. Conclusions: Dogs affected by spontaneous cancers are useful models for evaluating the efficacy of drug delivery systems containing antitumor compounds.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Veterinary Oncology Research · Cancer Research and Treatments · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Health Sciences, University “Magna Græcia” of Catanzaro, Campus Universitario “S Venuta”, I-88100 Catanzaro, Italy

References (100+)

Show source-provided references
1. Mortality in North American Dogs from 1984 to 2004: An Investigation into Age-, Size-, and Breed-related Causes of Death10.1111/j.1939-1676.2011.0695.x ↗
2. Domestic Dogs and Cancer Research: A Breed-Based Genomics Approach10.1093/ilar/ilu017 ↗
3. Horizons in Veterinary Precision Oncology: Fundamentals of Cancer Genomics and Applications of Liquid Biopsy for the Detection, Characterization, and Management of Cancer in Dogs10.3389/fvets.2021.664718 ↗
4. Translation of New Cancer Treatments from Pet Dogs to Humans10.1038/nrc2273 ↗
5. Canine Cancer Genomics: Lessons for Canine and Human Health10.1146/annurev-animal-030117-014523 ↗
6. A Comprehensive Overview of Oncogenic Pathways in Human Cancer10.1093/bib/bbz046 ↗
7. Current Challenges in Cancer Treatment10.1016/j.clinthera.2016.03.026 ↗
8. Mechanisms of Receptor Tyrosine Kinase Activation in Cancer10.1186/s12943-018-0782-4 ↗
9. Global Cancer Patterns: Causes and Prevention10.1016/S0140-6736(13)62224-2 ↗
10. 2016 AAHA Oncology Guidelines for Dogs and Cats10.5326/JAAHA-MS-6570 ↗
11. Metronomic Chemotherapy in Veterinary Patients with Cancer: Rethinking the Targets and Strategies of Chemotherapy10.1016/j.cvsm.2014.05.003 ↗
12. Nanocarriers for the Delivery of Medical, Veterinary, and Agricultural Active Ingredients10.1021/acsnano.0c00173 ↗
13. Biodegradable Polymeric Nanoparticles for Drug Delivery to Solid Tumors10.3389/fphar.2021.601626 ↗
14. Surface-Modified Polymeric Nanoparticles for Drug Delivery to Cancer Cells10.1080/17425247.2020.1822321 ↗
15. Intelligent Design of Ultrasmall Iron Oxide Nanoparticle-Based Theranostics10.1021/acsami.1c13341 ↗
16. Liposomes Modified with Bio-Substances for Cancer Treatment10.1039/D0BM01531H ↗
17. Comparative Oncology: What Dogs and Other Species Can Teach Us about Humans with Cancer10.1098/rstb.2014.0231 ↗
18. Naturally Occurring Cancers in Dogs: Insights for Translational Genetics and Medicine10.1093/ilar/ilu010 ↗
19. The Role of Clinical Trials in Veterinary Oncology10.1016/j.cvsm.2014.05.006 ↗
20. Improving Human Cancer Therapy through the Evaluation of Pet Dogs10.1038/s41568-020-0297-3 ↗
21. Beyond Tradition and Convention: Benefits of Non-Traditional Model Organisms in Cancer Research10.1007/s10555-020-09930-6 ↗
22. A Comparison of Risk Factors for Metastasis at Diagnosis in Humans and Dogs with Osteosarcoma10.1002/cam4.2177 ↗
23. Occupational Exposure to Pesticides and Bladder Cancer Risk10.1093/ije/dyv195 ↗
24. Bladder Cancer in Pet Dogs: A Sentinel for Environmental Cancer?10.1093/oxfordjournals.aje.a113186 ↗
25. Liposomes in Biology and Medicine10.1007/978-0-387-76713-0_9 ↗
26. Pros and Cons of the Liposome Platform in Cancer Drug Targeting10.1080/08982100600848769 ↗
27. Liposomes as Multicompartmental Carriers for Multidrug Delivery in Anticancer Chemotherapy10.1007/s13346-010-0007-x ↗
28. FDA Approval Summary:(Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid LeukemiaFDA Approval:(Daunorubicin and Cytarabine)10.1158/1078-0432.CCR-18-2990 ↗
29. García-Pinel, B., Porras-Alcalá, C., Ortega-Rodríguez, A., Sarabia, F., Prados, J., Melguizo, C., and López-Romero, J.M. (2019). Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment. Nanomaterials, 9.10.3390/nano9040638 ↗
30. Polyethylene Glycol (PEG)-Dendron Phospholipids as Innovative Constructs for the Preparation of Super Stealth Liposomes for Anticancer Therapy10.1016/j.jconrel.2014.12.008 ↗
31. To PEGylate or Not to PEGylate: Immunological Properties of Nanomedicine’s Most Popular Component, Poly (Ethylene) Glycol and Its Alternatives10.1016/j.addr.2021.114079 ↗
32. Animal Models of Complement-Mediated Hypersensitivity Reactions to Liposomes and Other Lipid-Based Nanoparticles10.1080/08982100701375118 ↗
33. Nanocarriers for Cancer-Targeted Drug Delivery10.3109/1061186X.2015.1051049 ↗
34. Strategies in the Design of Nanoparticles for Therapeutic Applications10.1038/nrd2591 ↗
35. Doxil®—The First FDA-Approved Nano-Drug: Lessons Learned10.1016/j.jconrel.2012.03.020 ↗
36. Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date10.1007/s11095-016-1958-5 ↗
37. Preclinical Safety, Pharmacokinetics and Antitumor Efficacy Profile of Liposome-Entrapped SN-38 Formulation
38. Phase I Trial of Doxorubicin-Containing Low Temperature Sensitive Liposomes in Spontaneous Canine Tumors10.1158/1078-0432.CCR-06-0226 ↗
39. A Novel Method to Load Topotecan into Liposomes Driven by a Transmembrane NH4EDTA Gradient10.1016/j.ejpb.2011.10.013 ↗
40. Preparation and the In-Vivo Evaluation of Paclitaxel Liposomes for Lung Targeting Delivery in Dogs10.1111/j.2042-7158.2010.01184.x ↗
41. Liposomal Topotecan Formulation with a Low Polyethylene Glycol Grafting Density: Pharmacokinetics and Antitumour Activity10.1111/j.2042-7158.2011.01422.x ↗
42. Aluminum-Chloride-Phthalocyanine Encapsulated in Liposomes: Activity against Naturally Occurring Dog Breast Cancer Cells10.1166/jbn.2012.1378 ↗
43. Marqibo®(Vincristine Sulfate Liposome Injection) Improves the Pharmacokinetics and Pharmacodynamics of Vincristine10.1007/s00280-012-2042-4 ↗
44. Pharmacokinetics and Biodistribution Study of Paclitaxel Liposome in Sprague-Dawley Rats and Beagle Dogs by Liquid Chromatography-Tandem Mass Spectrometry10.1055/s-0033-1349126 ↗
45. Pharmacokinetics of Liposomal-Encapsulated and Un-Encapsulated Vincristine after Injection of Liposomal Vincristine Sulfate in Beagle Dogs10.1007/s00280-013-2369-5 ↗
46. Preparation, Pharmacokinetic Profile, and Tissue Distribution Studies of a Liposome-Based Formulation of SN-38 Using an UPLC–MS/MS Method10.1208/s12249-016-0484-4 ↗
47. Pharmacokinetics of Multivesicular Liposomal Encapsulated Cytarabine When Administered Subcutaneously in Dogs10.1111/jvim.15809 ↗
48. Localized Delivery of Therapeutic Doxorubicin Dose across the Canine Blood–Brain Barrier with Hyperthermia and Temperature Sensitive Liposomes10.1080/10717544.2018.1461280 ↗
49. In Vitro Effects of the Chemotherapy Agent Water-soluble Micellar Paclitaxel (Paccal Vet) on Canine Hemangiosarcoma Cell Lines10.1111/vco.12442 ↗
50. Effect of the NFL-TBS. 40-63 Peptide on Canine Glioblastoma Cells10.1016/j.ijpharm.2021.120811 ↗
51. Immune Modulatory Nanoparticle Therapeutics for Intracerebral Glioma
52. Response to Liposome-encapsulated Doxorubicin (TLC D-99) in a Dog with Myeloma10.1111/j.1939-1676.1995.tb03304.x ↗
53. Preclinical Trial of Doxorubicin Entrapped in Sterically Stabilized Liposomes in Dogs with Spontaneously Arising Malignant Tumors10.1007/s002800050591 ↗
54. A Randomized Controlled Study into the Efficacy and Toxicity of Pegylated Liposome Encapsulated Doxorubicin as an Adjuvant Therapy in Dogs with Splenic Haemangiosarcoma10.1111/j.1476-5829.2011.00266.x ↗
55. Van Clinical and Pharmacokinetic Characteristics of Intracavitary Administration of Pegylated Liposomal Encapsulated Doxorubicin in Dogs with Splenic Hemangiosarcoma10.1111/j.1939-1676.2007.tb01958.x ↗
56. Chemotherapy-Induced Acral Erythema: A Clinical and Histopathologic Study of 44 Cases
57. Efficacy of Pyridoxine to Ameliorate the Cutaneous Toxicity Associated with Doxorubicin Containing Pegylated (Stealth) Liposomes: A Randomized, Double-Blind Clinical Trial Using a Canine Model
58. STEALTH Liposome-Encapsulated Cisplatin (SPI-77) versus Carboplatin as Adjuvant Therapy for Spontaneously Arising Osteosarcoma (OSA) in the Dog: A Randomized Multicenter Clinical Trial10.1007/s00280-002-0469-8 ↗
59. Evaluation of a Short-Term Saline Diuresis Protocol for the Administration of Cisplatin
60. Personalized Tumor RNA Loaded Lipid-Nanoparticles Prime the Systemic and Intratumoral Milieu for Response to Cancer Immunotherapy10.1021/acs.nanolett.8b02179 ↗
61. Liposome–DNA Complexes Infused Intravenously Inhibit Tumor Angiogenesis and Elicit Antitumor Activity in Dogs with Soft Tissue Sarcoma10.1038/sj.cgt.7700895 ↗
62. Current Studies of Liposome Muramyl Tripeptide (CGP 19835A Lipid) Therapy for Metastasis in Spontaneous Tumors: A Progress Review10.3109/10611869408996814 ↗
63. Adjuvant Therapy for Osteosarcoma in Dogs: Results of Randomized Clinical Trials Using Combined Liposome-Encapsulated Muramyl Tripeptide and Cisplatin
64. Liposome-Encapsulated Muramyl Tripeptide Phosphatidylethanolamine Adjuvant Immunotherapy for Splenic Hemangiosarcoma in the Dog: A Randomized Multi-Institutional Clinical Trial
65. Liposome-Encapsulated Muramyl Tripeptide Phosphatidyl-Ethanolamine (L-MTP-PE): A Randomized Clinical Trial in Dogs with Mammary Carcinoma
66. Adjuvant Therapy for Melanoma in Dogs: Results of Randomized Clinical Trials Using Surgery, Liposome-Encapsulated Muramyl Tripeptide, and Granulocyte Macrophage Colony-Stimulating Factor
68. Evaluation of Liposomal Clodronate for Treatment of Malignant Histiocytosis in Dogs10.1007/s00262-009-0763-y ↗
69. In Vitro and in Vivo Activity of Liposome-encapsulated Curcumin for Naturally Occurring Canine Cancers10.1111/vco.12424 ↗
70. Bioavailability of Curcumin: Problems and Promises10.1021/mp700113r ↗
71. Infusion Pharmacokinetics of LipocurcTM (Liposomal Curcumin) and Its Metabolite Tetrahydrocurcumin in Beagle Dogs
72. Nanostructured Lipid Carriers: Promising Drug Delivery Systems for Future Clinics10.1016/j.nano.2015.09.004 ↗
73. 50 Years of Oral Lipid-Based Formulations: Provenance, Progress and Future Perspectives10.1016/j.addr.2016.04.007 ↗
74. Mainini, F., and Eccles, M.R. (2020). Lipid and Polymer-Based Nanoparticle SiRNA Delivery Systems for Cancer Therapy. Molecules, 25.10.3390/molecules25112692 ↗
75. Cancer Theranostic Applications of Lipid-Based Nanoparticles10.1016/j.drudis.2018.04.007 ↗
76. A Randomized Trial Investigating the Efficacy and Safety of Water Soluble Micellar Paclitaxel (Paccal Vet) for Treatment of Nonresectable Grade 2 or 3 Mast Cell Tumors in Dogs10.1111/j.1939-1676.2012.00897.x ↗
77. A Dose-finding Study with a Novel Water-soluble Formulation of Paclitaxel for the Treatment of Malignant High-grade Solid Tumours in Dogs10.1111/j.1476-5829.2011.00314.x ↗
78. Hypocholesterolemia in Cancer Patients May Be Caused by Elevated LDL Receptor Activities in Malignant Cells10.1007/BF02934541 ↗
79. Design and Encapsulation of Anticancer Dual HSP27 and HER2 Inhibitor into Low Density Lipoprotein to Target Ovarian Cancer Cells10.1016/j.jsps.2020.01.020 ↗
80. Pilot Clinical Study of Carmustine Associated with a Lipid Nanoemulsion in Combination with Vincristine and Prednisone for the Treatment of Canine Lymphoma10.1111/vco.12033 ↗
81. Paclitaxel-Loaded Gelatin Nanoparticles for Intravesical Bladder Cancer Therapy10.1158/1078-0432.CCR-04-1443 ↗
82. Canine Model of Convection-Enhanced Delivery of Cetuximab-Conjugated Iron-Oxide Nanoparticles Monitored with Magnetic Resonance Imaging10.1227/NEU.0b013e31826989ef ↗
83. Effects of Intratumoral Administration of a Hyaluronan-Cisplatin Nanoconjugate to Five Dogs with Soft Tissue Sarcomas10.2460/ajvr.73.12.1969 ↗
84. Paclitaxel Gelatin Nanoparticles for Intravesical Bladder Cancer Therapy10.1016/j.juro.2010.11.091 ↗
85. Hyaluronan-Lysine Cisplatin Drug Carrier for Treatment of Localized Cancers: Pharmacokinetics, Tolerability, and Efficacy in Rodents and Canines10.1016/j.xphs.2016.03.018 ↗
86. Multifunctional Targeting Micelle Nanocarriers with Both Imaging and Therapeutic Potential for Bladder Cancer
87. Targeting Tumor Vasculature with Aptamer-Functionalized Doxorubicin–Polylactide Nanoconjugates for Enhanced Cancer Therapy10.1021/acsnano.5b00166 ↗
88. Evaluation of Nanoparticle Delivered Cisplatin in Beagles10.1039/C5NR03447G ↗
89. PEGylated Lipid Bilayer Coated Mesoporous Silica Nanoparticles for Co-Delivery of Paclitaxel and Curcumin: Design, Characterization and Its Cytotoxic Effect10.1016/j.ijpharm.2017.10.043 ↗
90. Toxicity and Safety Evaluation of Doxorubicin-Loaded Cockleshell-Derived Calcium Carbonate Nanoparticle in Dogs
91. Małek, A., Taciak, B., Sobczak, K., Grzelak, A., Wójcik, M., Mieczkowski, J., Lechowski, R., and Zabielska-Koczywąs, K.A. (2021). Enhanced Cytotoxic Effect of Doxorubicin Conjugated to Glutathione-Stabilized Gold Nanoparticles in Canine Osteosarcoma—In Vitro Studies. Molecules, 26.10.3390/molecules26123487 ↗
92. Phase I-II Clinical Trial of Hyaluronan-Cisplatin Nanoconjugate in Dogs with Naturally Occurring Malignant Tumors10.2460/ajvr.77.9.1005 ↗
93. Gagliardi, A., Voci, S., Paolino, D., Fresta, M., and Cosco, D. (2020). Influence of Various Model Compounds on the Rheological Properties of Zein-Based Gels. Molecules, 25.10.3390/molecules25143174 ↗
94. Theranostic Polymeric Nanoparticles for NIR Imaging and Photodynamic Therapy10.1016/j.ijpharm.2018.09.019 ↗
95. V Plant-Derived Bioadhesives for Wound Dressing and Drug Delivery System10.1016/j.fitote.2019.104241 ↗
96. Quantitative Proteomic Analysis of Cellular Resistance to the Nanoparticle Abraxane10.1021/acsnano.5b03677 ↗
97. Injectable Chemotherapy Downstaged Oral Squamous Cell Carcinoma from Nonresectable to Resectable in a Rescue Dog: Diagnosis, Treatment, and Outcome
98. Pharmacokinetics and Disposition of a Localized Lymphatic Polymeric Hyaluronan Conjugate of Cisplatin in Rodents10.1002/jps.22016 ↗
99. Pamidronate Functionalized Nanoconjugates for Targeted Therapy of Focal Skeletal Malignant Osteolysis10.1073/pnas.1603316113 ↗
100. The Epidemiology of Osteosarcoma10.1007/978-1-4419-0284-9_1 ↗